BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Humira is a prescription medication approved by the Food and Drug Administration (FDA) to treat adults with active ankylosing spondylitis. Humira is also indicated to treat uveitis, a type of eye inflammation that develops in 25 to 40 percent of people with spondyloarthritis. Humira may be prescribed in cases where other drugs have proven ineffective or intolerable. Humira is also known by its drug name, Adalimumab.
Humira is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Humira is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Humira is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
After an initial loading dose, Humira is administered every other week by subcutaneous injection.
Humira is available as a pen or prefilled syringe.
The FDA-approved label for Humira lists common side effects including respiratory infections, headache, redness or irritation at injection sites, and rash.
Rare but serious side effects listed for Humira include severe allergic reactions, potentially fatal infections, and increased risk for developing certain types of cancer such as lymphoma.
For answers to frequently asked questions about exposure to Humira during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Humira – AbbVie
Management of Uveitis in Spondyloarthropathy: Current Trends - The Permanente Journal